01.12.20: not for release, publication or distribution in any jurisdiction in which such release, publication or distribution would be unlawful
Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completionmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 1, 2020 Category: Pharmaceuticals Source Type: news

17.11.20: Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular diseaseIn the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes, overall finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease / People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Finere...
Source: Bayer IR Newsfeed: Events - November 17, 2020 Category: Pharmaceuticals Source Type: news

13.11.20: Not intended for U.S. and UK Media
Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in childrenPediatric patients currently have limited therapeutic options and until now, there have been no approved oral treatments because of the absence of appropriate clinical trials / After approval, rivaroxaban would be the only oral Factor Xa Inhibitor authorized to treat VTE and prevent VTE recurrence in children / An oral suspension of rivaroxaban that does not require injections or regular monitoring has been developed to facilitate pediatric administration / CHMP opinion is based on the largest pediatr...
Source: Bayer IR Newsfeed: Events - November 13, 2020 Category: Pharmaceuticals Source Type: news

12.11.20: Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt FundMetagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases / Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient access to cell and gene therapiesmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 12, 2020 Category: Pharmaceuticals Source Type: news

09.11.20: Not intended for U.S. and UK Media
Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetesRegulatory submissions based on positive data from Phase III FIDELIO-DKD study recently published in the New England Journal of Medicinemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 10, 2020 Category: Pharmaceuticals Source Type: news

05.08.21: 2021 Half-Year Report
2021 Half-Year ReportLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 3, 2020 Category: Pharmaceuticals Source Type: news

03.11.20: Bayer:
Challenging third quarter - Group outlook confirmedGroup sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion euros / Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects / Pharmaceuticals business recovering - higher earnings but slightly lower sales / Strong performance at Consumer Health / Net loss of 2.744 billion euros - impairment charges at Crop Science, proceeds from divestment of Animal Health / Core earnings per share decline by 30.2 percent to 0.81 euros / Free cash ...
Source: Bayer IR Newsfeed: Events - November 3, 2020 Category: Pharmaceuticals Source Type: news

09.11.20: Redburn Virtual Canada Conference
Redburn Virtual Canada ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 30, 2020 Category: Pharmaceuticals Source Type: news

10.11.20: Morgan Stanley Virtual Global Chemicals Conference
Morgan Stanley Virtual Global Chemicals ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 30, 2020 Category: Pharmaceuticals Source Type: news

27.10.20: The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer's low-volatility dicamba product
The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer's low-volatility dicamba productThe new registration follows launch announcement for XtendFlex® soybeans and enables full potential of industry-leading Roundup Ready® Xtend Crop Systemmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 28, 2020 Category: Pharmaceuticals Source Type: news

27.10.20: Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Development
Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Developmentmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 28, 2020 Category: Pharmaceuticals Source Type: news

26.10.20: Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapyAcquisition fuels Bayer's cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as ...
Source: Bayer IR Newsfeed: Events - October 26, 2020 Category: Pharmaceuticals Source Type: news

23.10.20: Not intended for U.S. and UK Media
FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patientsThe companion diagnostic (CDx) approval is part of the global collaboration between Bayer and Foundation Medicine, Inc. for the development and commercialization of next-generation sequencing (NGS)-based companion diagnostics in oncology / Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, such as available biomarker driven therapies / FoundationOne®CDx analyzes substitutions, insertion and deleti...
Source: Bayer IR Newsfeed: Events - October 24, 2020 Category: Pharmaceuticals Source Type: news

23.10.20: Not intended for U.S. and UK Media - Data from Phase III FIDELIO-DKD study presented at the American Society of Nephrology (ASN)'s Kidney Week 2020
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Finerenone specifically addresses MR overactivation, a key driver of disease progression / Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events / Results...
Source: Bayer IR Newsfeed: Events - October 23, 2020 Category: Pharmaceuticals Source Type: news

03.11.20: News Conference Call Third Quarter 2020 Results
News Conference Call Third Quarter 2020 ResultsLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 21, 2020 Category: Pharmaceuticals Source Type: news

03.11.20: Q3 2020 Investor Conference Call
Q3 2020 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 20, 2020 Category: Pharmaceuticals Source Type: news

19.10.20: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 18, 2020 Category: Pharmaceuticals Source Type: news

14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news

12.10.20: Not intended for U.S. and UK Media - American Society of Nephrology (ASN)'s Kidney Week 2020 Reimagined:
Finerenone Phase III FIDELIO-DKD study in chronic kidney disease and type 2 diabetes to be presented as late-breaking clinical trial at ASN 2020FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) with a primary composite endpoint consisting exclusively of kidney-specific outcomes / Finerenone, a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist, demonstrated positive renal and cardiovascular outcomes in patients with CKD and T2D / Preclinical data on finerenone, as well as a range of post...
Source: Bayer IR Newsfeed: Events - October 13, 2020 Category: Pharmaceuticals Source Type: news

30.09.20: Bayer to accelerate transformation to address challenging market environment and enable additional growth investments
Bayer to accelerate transformation to address challenging market environment and enable additional growth investmentsAdjusted outlook for 2020 confirmed / 2021 sales expected at approximately 2020 levels despite significant headwinds from COVID-19 pandemic; 2021 core earnings per share expected to be slightly below 2020 levels at constant exchange rates / Lower than expected outlook in the agricultural market likely to lead to mid-to-high single-digit billion-euro non-cash impairment charges in the Crop Science business / Strengthening margin profile and funding of additional investments in innovation and growth through ad...
Source: Bayer IR Newsfeed: Events - October 1, 2020 Category: Pharmaceuticals Source Type: news

28.09.20: Not intended for U.S. and UK Media
Bayer's XtendFlex Soybeans Gain Final Key Regulatory ApprovalEuropean Commission's Green Light Enables a Full Launch in 2021mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 29, 2020 Category: Pharmaceuticals Source Type: news

17.09.20: ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integ...
Source: Bayer IR Newsfeed: Events - September 17, 2020 Category: Pharmaceuticals Source Type: news

15.09.20: Not intended for U.S. and UK Media
Bayer and Systems Oncology sign exclusive license agreement on innovative breast cancer treatment approach ERSO™ mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 16, 2020 Category: Pharmaceuticals Source Type: news

10.09.20: Bayer: Supervisory Board extends CEO Werner Baumann's contract until the end of April 2024
Bayer: Supervisory Board extends CEO Werner Baumann's contract until the end of April 2024Company also announces progress in Roundup™ settlementsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 11, 2020 Category: Pharmaceuticals Source Type: news

09.09.20: Not intended for U.S. and UK Media
New England Journal of Medicine publishes final overall survival data for Nubeqa™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancerMen with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety ...
Source: Bayer IR Newsfeed: Events - September 10, 2020 Category: Pharmaceuticals Source Type: news

09.09.20: Not intended for U.S. and UK Media
Bayer completes acquisition of UK-based biotech company KaNDy Therapeutics Ltd.mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 9, 2020 Category: Pharmaceuticals Source Type: news

09.09.20: Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases
Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseasesDrug Discovery partnership and equity investment led by Leaps by Bayer in Series D financing round / Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients fastermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 8, 2020 Category: Pharmaceuticals Source Type: news

08.09.20: Not intended for U.S. and UK Media
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dic...
Source: Bayer IR Newsfeed: Events - September 8, 2020 Category: Pharmaceuticals Source Type: news

15.09.20: Morgan Stanley Virtual Global Healthcare Conference
Morgan Stanley Virtual Global Healthcare ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news

17.09.20: BofA Virtual Global Healthcare Conference
BofA Virtual Global Healthcare ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news

17.09.20: Credit Suisse Annual Virtual Basic Materials Conference
Credit Suisse Annual Virtual Basic Materials ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news

21.09.20: Berenberg and Goldman Sachs Virtual German Corporate Conference
Berenberg and Goldman Sachs Virtual German Corporate ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news

23.09.20: Bernstein Virtual Strategic Decision Conference
Bernstein Virtual Strategic Decision ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news

24.09.20: Bernstein Virtual Strategic Decision Conference
Bernstein Virtual Strategic Decision ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news

28.08.20: Not intended for U.S. and UK Media
Bayer submits vericiguat for marketing authorization in China for the treatment of chronic heart failuremehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 28, 2020 Category: Pharmaceuticals Source Type: news

27.08.20: Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira Immunologics
Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira ImmunologicsLeaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments / Triumvira's T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight cancer / Pipeline includes four therapeutic candidates for both autologous and allogeneic T-cell immuno therapies for treatment of liquid and solid tumorsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 27, 2020 Category: Pharmaceuticals Source Type: news

27.08.20: Not intended for U.S. and UK Media
Bayer receives approval for Xofigo® in Chinamehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 26, 2020 Category: Pharmaceuticals Source Type: news

24.08.20: Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas
Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areasDeal value up to USD 98 million including increased equity stake and joint development of digital health platform / Collaboration reinforces Bayer's commitment to developing integrated care solutions for patientsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 24, 2020 Category: Pharmaceuticals Source Type: news

17.09.20: ESG Investor Conference Call
ESG Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 21, 2020 Category: Pharmaceuticals Source Type: news

21.08.20: More than 950 companies join in the fight against climate change
Science Based Targets initiative endorses climate protection targets of Bayer AGImportant step in Bayer becoming climate-neutral by 2030 / Targets integral to Board of Management remunerationmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 21, 2020 Category: Pharmaceuticals Source Type: news

20.08.20: Bayer announces resolution of U.S. Essure™ claims
Bayer announces resolution of U.S. Essure™ claimsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 20, 2020 Category: Pharmaceuticals Source Type: news

12.08.20: Bayer and Temasek unveil innovative new company focused on developing breakthroughs in vertical farming
Bayer and Temasek unveil innovative new company focused on developing breakthroughs in vertical farmingInitial efforts will focus on innovating vegetable varieties that deliver optimized quality and sensory experience / Called Unfold, the new company will be headquartered in the Davis, Calif., area with key operations in both the U.S. and Singapore / John Purcell appointed as CEOmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 13, 2020 Category: Pharmaceuticals Source Type: news

11.08.20: Not intended for U.S. and UK Media
Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd.Further expansion of Bayer's drug development pipeline in Women's Healthcare / Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms / Development compound recently completed Phase IIb / Reinforces Bayer's position in Women's Healthcare / Upfront consideration of USD 425 million and additional potential consideration in the form of milestone paymentsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 10, 2020 Category: Pharmaceuticals Source Type: news

05.08.20: Post Q2 Virtual Roadshow
Post Q2 Virtual RoadshowLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 4, 2020 Category: Pharmaceuticals Source Type: news

04.08.20: Second quarter of 2020:
Bayer: Solid performance despite COVID-19 impactEnsuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx & portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx & portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations - agreements in m...
Source: Bayer IR Newsfeed: Events - August 4, 2020 Category: Pharmaceuticals Source Type: news

04.08.20: Post Q2 Virtual Roadshow
Post Q2 Virtual RoadshowLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 3, 2020 Category: Pharmaceuticals Source Type: news

03.08.20: Bayer completes the sale of its Animal Health business unit to Elanco
Bayer completes the sale of its Animal Health business unit to Elancomehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 3, 2020 Category: Pharmaceuticals Source Type: news

04.08.20: Q2 2020 Investor Conference Call
Q2 2020 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 21, 2020 Category: Pharmaceuticals Source Type: news

21.07.20: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 20, 2020 Category: Pharmaceuticals Source Type: news

16.07.20: Not intended for U.S. and UK Media
U.S. FDA grants priority review to New Drug Application for vericiguat to treat chronic heart failuremehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 16, 2020 Category: Pharmaceuticals Source Type: news